Table 1.
Demographic characteristics of 22,458 patients with stage IIIB or IV NSCLC without initial brain metastasis.
| Total patients (n = 22,458, 100%) | Patients with subsequent BM (n = 1,126, 5.0%) | Patients without subsequent BM (n = 21,332, 95.0%) | P-value | |
|---|---|---|---|---|
| Age | 67.23 ± 10.31 | 61.87 ± 10.86 | 67.51 ± 10.20 | <0.0001 |
| Sex (M/F) | 14,555/7,903 | 493/633 | 14,062/7,270 | <0.0001 |
| Medical condition | ||||
| HBP | 11,202 (49.9%) | 487 (43.3%) | 10,715 (50.2%) | <0.0001 |
| DM | 4,706 (21.0%) | 195 (17.3%) | 4,511 (21.1%) | <0.0001 |
| COPD | 896 (4.0%) | 22 (2.0%) | 874 (4.1%) | <0.0001 |
| Anticoagulation user | 542 (2.4%) | 31 (2.8%) | 511 (2.4%) | <0.0001 |
| Antiplatelet user | 6,535 (29.1%) | 278 (24.7%) | 6,257 (29.3%) | <0.0001 |
| First line treatment | ||||
| Cytotoxic chemotherapy | 16,119 (71.8%) | 576 (51.2%) | 15,543 (72.9%) | <0.0001 |
| Targeted therapy | 6,339 (28.2%) | 550 (48.8%) | 5,789 (27.1%) | |
Abbreviations: BM, brain metastasis; HBP, hypertension; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease.